ARTICLE | Company News
Biogen Idec, Ophthotech, PDL BioPharma deal
January 14, 2008 8:00 AM UTC
Biogen Idec and PDL granted Ophthotech an exclusive, worldwide license to develop and commercialize volociximab (M200) for ophthalmic indications. Ophthotech plans to develop the mAb against integrin...